{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:18Z","timestamp":1793502918532,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00198-017-4009-0","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T19:43:36Z","timestamp":1493322216000},"page":"2023-2034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":145,"title":["Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting"],"prefix":"10.1007","volume":"28","author":[{"given":"J. A.","family":"Kanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. M.","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cannata-Andia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Dimai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kraenzlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"4009_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"4009_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12877-016-0349-4","volume":"16","author":"C Beaudart","year":"2016","unstructured":"Beaudart C, McCloskey E, Bruyere O et al (2016) Sarcopenia in daily practice: assessment and management. BMC Geriatr 16:170","journal-title":"BMC Geriatr"},{"key":"4009_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11657-010-0035-7","volume":"5","author":"N Freemantle","year":"2010","unstructured":"Freemantle N, Cooper C, Roux C et al (2010) Baseline observations from the POSSIBLE EU\u00ae study: characteristics of postmenopausal women receiving bone loss medications. Arch Osteoporos 5:61\u201372","journal-title":"Arch Osteoporos"},{"key":"4009_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","volume":"25","author":"H Johansson","year":"2014","unstructured":"Johansson H, Od\u00e9n A, McCloskey EV, Kanis JA (2014) Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporosis Int 25:235\u2013241","journal-title":"Osteoporosis Int"},{"key":"4009_CR5","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Od\u00e9n A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis Int 23:2239\u20132256","journal-title":"Osteoporosis Int"},{"key":"4009_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00198-011-1601-6","volume":"22","author":"C Cooper","year":"2011","unstructured":"Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA, Epidemiology ICWGoF (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277\u20131288","journal-title":"Osteoporos Int"},{"key":"4009_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","volume":"87","author":"EM Curtis","year":"2016","unstructured":"Curtis EM, van der Velde R, Moon RJ, van den Bergh JP, Geusens P, de Vries F, van Staa TP, Cooper C, Harvey NC (2016) Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87:19\u201326","journal-title":"Bone"},{"key":"4009_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00198-006-0245-4","volume":"18","author":"O Johnell","year":"2007","unstructured":"Johnell O, Borgstrom F, Jonsson B, Kanis J (2007) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18:333\u2013337","journal-title":"Osteoporos Int"},{"key":"4009_CR9","unstructured":"Lucas RM, Severo A, Silva M, Monjardino P, Gaio T, Cooper AR, Barros H (2017) Is there a shared hip fracture epidemic in Europe? Modelling recent time trends in 14 countries. Submitted for publication"},{"key":"4009_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00198-016-3768-3","volume":"28","author":"BE Rosengren","year":"2016","unstructured":"Rosengren BE, Bjork J, Cooper C, Abrahamsen B (2016) Recent hip fracture trends in Sweden and Denmark with age-period-cohort effects. Osteoporos Int 28:139\u2013149","journal-title":"Osteoporos Int"},{"key":"4009_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"key":"4009_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","volume":"8","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 8:144","journal-title":"Arch Osteoporos"},{"key":"4009_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-012-1968-z","volume":"24","author":"G Ioannidis","year":"2013","unstructured":"Ioannidis G, Flahive J, Pickard L et al (2013) Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int 24:59\u201367","journal-title":"Osteoporos Int"},{"key":"4009_CR14","doi-asserted-by":"crossref","unstructured":"Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775\u2013780","DOI":"10.1007\/s00198-016-3868-0"},{"key":"4009_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00198-003-1514-0","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175\u2013179","journal-title":"Osteoporos Int"},{"key":"4009_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s001980170131","volume":"12","author":"O Johnell","year":"2001","unstructured":"Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207\u2013214","journal-title":"Osteoporos Int"},{"key":"4009_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1359\/jbmr.090207","volume":"24","author":"J Ryg","year":"2009","unstructured":"Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res 24:1299\u20131307","journal-title":"J Bone Miner Res"},{"key":"4009_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1532-5415.2011.03854.x","volume":"60","author":"SL Greenspan","year":"2012","unstructured":"Greenspan SL, Wyman A, Hooven FH et al (2012) Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc 60:455\u2013461","journal-title":"J Am Geriatr Soc"},{"key":"4009_CR19","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929\u20131937","journal-title":"J Bone Miner Res"},{"key":"4009_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00198-005-0010-0","volume":"17","author":"V Carnevale","year":"2006","unstructured":"Carnevale V, Nieddu L, Romagnoli E, Bona E, Piemonte S, Scillitani A, Minisola S (2006) Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 17:478\u2013483","journal-title":"Osteoporos Int"},{"key":"4009_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00198-010-1359-2","volume":"22","author":"LA Fraser","year":"2011","unstructured":"Fraser LA, Ioannidis G, Adachi JD et al (2011) Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 22:789\u2013796","journal-title":"Osteoporos Int"},{"key":"4009_CR22","doi-asserted-by":"crossref","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, Rizzoli R, Cooper C, Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int","DOI":"10.1007\/s00198-016-3894-y"},{"key":"4009_CR23","doi-asserted-by":"crossref","unstructured":"Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E (2016) Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res 32:424\u201343","DOI":"10.1002\/jbmr.3074"},{"key":"4009_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","volume":"94","author":"RY van der Velde","year":"2017","unstructured":"van der Velde RY, Wyers CE, Teesselink E, Geusens PP, van den Bergh JP, de Vries F, Cooper C, Harvey NC, van Staa TP (2017) Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone 94:50\u201355","journal-title":"Bone"},{"key":"4009_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2013","unstructured":"Wysowski DK, Greene P (2013) Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone 57:423\u2013428","journal-title":"Bone"},{"key":"4009_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"23","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures\u2014the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23:433\u2013443","journal-title":"Osteoporos Int"},{"key":"4009_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23\u201357","journal-title":"Osteoporos Int"},{"key":"4009_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Od\u00e9n A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Arch Osteoporos 11:25","journal-title":"Arch Osteoporos"},{"key":"4009_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.3039","volume":"32","author":"SR Cummings","year":"2016","unstructured":"Cummings SR, Cosman F, Lewiecki EM et al (2016) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res 32:3\u201310","journal-title":"J Bone Miner Res"},{"key":"4009_CR30","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/jbmr.2301","volume":"29","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926\u20131928","journal-title":"J Bone Miner Res"},{"key":"4009_CR31","doi-asserted-by":"publisher","first-page":"S624","DOI":"10.1007\/s00198-015-3406-5","volume":"27","author":"E McCloskey","year":"2016","unstructured":"McCloskey E, Lenaghan E, Clark S et al (2016) Screening based on FRAX fracture risk reduces the incidence of hip fractures in older community-dwelling women\u2014results from the SCOOP study. Osteoporos Int 27:S624","journal-title":"Osteoporos Int"},{"key":"4009_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00198-015-3443-0","volume":"27","author":"A Nakayama","year":"2016","unstructured":"Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int 27:873\u2013879","journal-title":"Osteoporos Int"},{"key":"4009_CR33","doi-asserted-by":"crossref","unstructured":"Leal J, Gray AM, Hawley S, Prieto-Alhambra D, Delmestri A, Arden NK, Cooper C, Javaid MK, Judge A, group REs (2016) Cost-effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: a population based study. J Bone Miner Res Sep 16","DOI":"10.1002\/jbmr.2995"},{"key":"4009_CR34","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00198-015-3192-0","volume":"26","author":"MK Javaid","year":"2015","unstructured":"Javaid MK, Kyer C, Mitchell PJ et al (2015) Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture\u00ae Best Practice Framework tool. Osteoporos Int 26:2573\u20132578","journal-title":"Osteoporos Int"},{"key":"4009_CR35","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00198-014-2755-9","volume":"25","author":"R Rizzoli","year":"2014","unstructured":"Rizzoli R, Branco J, Brandi ML et al (2014) Management of osteoporosis of the oldest old. Osteoporos Int 25:2507\u20132529","journal-title":"Osteoporos Int"},{"key":"4009_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/gerona\/glp003","volume":"64","author":"BD Lloyd","year":"2009","unstructured":"Lloyd BD, Williamson DA, Singh NA et al (2009) Recurrent and injurious falls in the year following hip fracture: a prospective study of incidence and risk factors from the Sarcopenia and Hip Fracture study. J Gerontol A Biol Sci Med Sci 64:599\u2013609","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"4009_CR37","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/jbmr.35","volume":"25","author":"LM Giangregorio","year":"2010","unstructured":"Giangregorio LM, Leslie WD, Manitoba Bone Density P (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 25:1400\u20131405","journal-title":"J Bone Miner Res"},{"key":"4009_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00223-014-9844-9","volume":"94","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Rizzoli R, Cooper C, Reginster JY (2014) Challenges for the development of bone-forming agents in Europe. Calcif Tissue Int 94:469\u2013473","journal-title":"Calcif Tissue Int"},{"key":"4009_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"4009_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"4009_CR41","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1210\/jc.2004-1774","volume":"90","author":"JY Reginster","year":"2005","unstructured":"Reginster JY, Seeman E, Vernejoul MCD et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816\u20132822","journal-title":"J Clin Endocrinol Metab"},{"key":"4009_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jbmr.2991","volume":"32","author":"F Cosman","year":"2017","unstructured":"Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM (2017) Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res 32:17\u201323","journal-title":"J Bone Miner Res"},{"key":"4009_CR43","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583\u20131587","journal-title":"J Clin Endocrinol Metab"},{"key":"4009_CR44","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, Adachi JD, Man Z et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96:1727\u20131736","journal-title":"J Clin Endocrinol Metab"},{"key":"4009_CR45","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522\u2013532","journal-title":"Bone"},{"key":"4009_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"4009_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5330","volume":"5","author":"ST Brookes","year":"2001","unstructured":"Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G (2001) Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess 5:1\u201356","journal-title":"Health Technol Assess"},{"key":"4009_CR48","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study. Osteoporosis Int 20:811\u2013817","journal-title":"Osteoporosis Int"},{"key":"4009_CR49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054","journal-title":"Bone"},{"key":"4009_CR50","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486","journal-title":"J Bone Miner Res"},{"key":"4009_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","volume":"47","author":"JA Kanis","year":"2010","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729\u2013735","journal-title":"Bone"},{"key":"4009_CR52","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int 22:2347\u20132355","journal-title":"Osteoporos Int"},{"key":"4009_CR53","first-page":"S381","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Johansson H, Harvey NC, Oden A, Jiang H, Modin S, Fitzpatrick L, Kanis JA (2016) Effect of investigational treatment abaloparatide-SC for prevention of major osteoporotic fracture or any fracture is independent of baseline fracture probability. J Bone Miner Metab 31:S381","journal-title":"J Bone Miner Metab"},{"key":"4009_CR54","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00198-015-3173-3","volume":"26","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Kanis JA, Oden A, Burge RT, Mitlak BH, Johansson H, McCloskey EV (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporos Int 26:2677\u20132684","journal-title":"Osteoporos Int"},{"key":"4009_CR55","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00198-015-3129-7","volume":"26","author":"NC Harvey","year":"2015","unstructured":"Harvey NC, Kanis JA, Od\u00e9n A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H, McCloskey EV (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporosis Int 26:2347\u20132353","journal-title":"Osteoporosis Int"},{"key":"4009_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. PharmacoEconomics 33:205\u2013224","journal-title":"PharmacoEconomics"},{"key":"4009_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-013-9724-8","volume":"93","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Kanis JA, Compston J et al (2013) Health technology assessment in osteoporosis. Calcif Tissue Int 93:1\u201314","journal-title":"Calcif Tissue Int"},{"key":"4009_CR58","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1359\/jbmr.090209","volume":"24","author":"EF Eriksen","year":"2009","unstructured":"Eriksen EF, Lyles KW, Colon-Emeric CS et al (2009) Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 24:1308\u20131313","journal-title":"J Bone Miner Res"},{"key":"4009_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11657-016-0292-1","volume":"11","author":"S Ferrari","year":"2016","unstructured":"Ferrari S, Reginster JY, Brandi ML, Kanis JA, Devogelaer JP, Kaufman JM, Feron JM, Kurth A, Rizzoli R (2016) Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Arch Osteoporos 11:37","journal-title":"Arch Osteoporos"},{"key":"4009_CR60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-016-3773-6","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, Biver E, Kaufman JM et al (2017) The role of calcium supplementation in healthy musculoskeletal ageing : an expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporos Int 28:447\u2013462","journal-title":"Osteoporos Int"},{"key":"4009_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.maturitas.2014.07.005","volume":"79","author":"R Rizzoli","year":"2014","unstructured":"Rizzoli R, Stevenson JC, Bauer JM et al (2014) The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas 79:122\u2013132","journal-title":"Maturitas"},{"key":"4009_CR62","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"key":"4009_CR63","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"4009_CR64","doi-asserted-by":"crossref","unstructured":"Ominsky MS, Boyce RW, Li X, Ke HZ (2016) Effects of sclerostin antibodies in animal models of osteoporosis. Bone Oct 24","DOI":"10.1016\/j.bone.2016.10.019"}],"updated-by":[{"DOI":"10.1007\/s00198-017-4161-6","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T00:00:00Z","timestamp":1502064000000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-017-4009-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T21:15:51Z","timestamp":1630617351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-017-4009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4009-0","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s00198-017-4161-6","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,27]]},"assertion":[{"value":"13 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An erratum to this article has been published.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos outside the submitted work. JAK is the architect of FRAX but has no financial interest. CC has received consultancy, lecture fees and honoraria from Amgen, GlaxoSmithKline, Alliance for Better Bone Health, Merck Sharp & Dohme, Eli Lilly, Pfizer, Novartis, Servier, Medtronic and Roche. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone and Nestl\u00e9. BA has institutional research contracts with Novartis and UCB outside of the submitted work. NMA-D has received support from the Prince Mutaib Chair for Biomarkers of Osteoporosis, Deanship of Scientific Research Chairs, King Saud University. MLB has received consultancy fees and grants from Alexion, Abiogen, Amgen, Eli Lilly and Shire. JC-A has received grants and\/or advisory board fees from Amgen, Servier, Fresenius-VIFOR and Shire. BC has received consultancy fees, lecture fees and honorarium from Amgen, Eli Lilly, Expanscience, Ferring, Medtronic, Novartis, Roche Diagnostics and Servier. HPD has received lecture fees, consulting fees and\/or advisory board fees from Amgen, Daiichi-Sankyo, Eli Lilly, Genericon, Kyphon, Merck Sharp & Dohme, Novartis, Nycomed, Servier and Sinapharm. SF has received grants or research support from Amgen and Merck Sharp & Dohme and consultancy fees from Amgen, Merck Sharp & Dohme, GlaxoSmithKline, Eli Lilly and UCB. PH has received grants, advisory board or speaker fees from Amgen, AstraZeneca, Eli Lilly, Exeltis, Daichii-Sankyo, Gedeon Richter, Meda, Merck Sharp & Dohme, Mylan, Novartis, Pfizer, Roche and UCB. NCH has received consultancy, lecture fees and honoraria from Alliance for Better Bone Health, Amgen, Merck Sharp & Dohme, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare and Internis Pharma. MK has no conflicts of interest to declare. AK has received consulting and speaker fees from Agnovos, Amgen, Eli Lilly, Novartis, Novo Nordisk, Roche, Servier, Biomet and Dfine, Inc. EM is or has acted as a consultant, advisor, speaker and\/or received research support from ActiveSignal, Amgen, Arthritis Research UK, AstraZeneca, Consilient Healthcare, EPSRC, GlaxoSmithKline, Hologic, I3 Innovus, Internis, the International Osteoporosis Foundation, Eli Lilly, the Medical Research Council, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Unilever and Warner Chilcott. SM has served as a speaker for Abiogen, Amgen, Diasorin, Eli Lilly, Italfarmaco, Fujii, Merck Sharp & Dohme and Takeda and on advisory boards for Amgen and Eli Lilly. TT has received advisory board or speaker fees from Amgen, Chugai\/Roche, Expanscience, Gen\u00e9vrier, GlaxoSmithKline, HAC-Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, Novartis, Teva and UCB and research grants or investigator fees from Amgen, Bone Therapeutics, Chugai\/Roche, LCA, Merck Sharp & Dohme, Novartis, Pfizer and UCB. J-YR has received advisory board or speaker fees from Asahi-Kasei, Eli Lilly, IBSA-Gen\u00e9vrier, Nycomed-Takeda, PharmEvo, Radius Health, Roche, Servier, UCB, Will Pharma and Zodiac.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}